- Leading Biotechnology Innovator Specializing in AI Chatbot Solutions for Early Drug Discovery, Infectious Disease and Neurodegenerative Disease Research.
- Focus on Developing Therapeutic Solutions by Leveraging Human Immune-B Cells for a Cutting-Edge Approach to Highly Effective Treatments.
- Strategic Investment Plan Demonstrating Commitment to Advancing Technological Capabilities and Expanding Reach in the AI Sector.
- Launch of Sutra (TM), a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research.
- AI Platform Confirmed Decades of Work and Added New Targets for Monoclonal Antibodies with Independent Validation of Their Potential from Collaborators.
- Growing IP Portfolio Including Patents, Trademarks and Trade Secrets.
- With a Database of 19 Viruses, the Sutra™ AI Platform Can Predict and Help Prevent Future Pandemics.
- Harnessing the Power of AI to Revolutionize Drug Repurposing, Offering a Cost-Effective Alternative to Developing New Drugs from the Ground Up.
1606 Corp. (OTC: CBDW) is a leading innovator in biotechnology, specializing in AI-driven solutions for early drug discovery, infectious disease, and neurodegenerative disease research. CBDW proprietary methods focus on developing therapeutic solutions by leveraging human immune-B cells, offering a cutting-edge approach to creating highly effective treatments.
CBDW has announced it has signed a Letter of Intent to acquire a strategic stake in Adnexus Biotechnologies Inc. CBDW stands at the forefront of technological innovation, particularly in AI Chatbots. It’s mission is to revolutionize customer service, addressing the most significant challenges faced by consumers in the digital marketplace. CBDW is dedicated to transforming the IR industry through cutting-edge AI centric solutions, ensuring a seamless and efficient customer experience.
CBDW specializes in the development and licensing of AI-powered chatbots, transforming how businesses communicate with their investors. CBDW is now a revenue generating AI technology development and sales company committed to enhancing the world of chatbots through the application of conversational artificial intelligence, and currently, CBDW AI is one of the fastest growing AI focused companies on the OTC Markets.
Generative AI Chatbots can provide instant, round-the-clock support, guiding potential investors through the company. Queries about dosage, usage, legality, while offering personalized recommendations based on individual preferences. Moreover, CBDW chatbots can handle multiple interactions simultaneously, ensuring no potential or existing investor feels neglected due to long response times. They also collect valuable data on investor preferences and behaviors, allowing companies to tailor their communication strategies more effectively. In the investor relations industry, where transparency and timely information are paramount, CBDW chatbots can provide up-to-date details on earnings reports, stock performance and company news. This immediate access to information builds confidence with investors, encouraging them to make informed decisions.
The global artificial intelligence market has seen remarkable growth, valued at $428 billion in 2022 and projected to reach $2.25 trillion by 2030. With a compound annual growth rate (CAGR) ranging from 33.2% to 38.1%, AI's global impact is undeniable, with as many as 97 million individuals expected to work in the AI sector by 2025, according to fortunebusinessinsights.com
Unveils Sutra (TM) is a Game-Changing AI Platform for Drug Discovery and Infectious Disease Research
On October 1st CBDW announced its new AI Empowered Drug Discovery Platform, Sutra™.
The CBDW Sutra™ AI platform has not just confirmed decades of work, but also added new targets for monoclonal antibodies within weeks, receiving independent validation of their potential from collaborators. CBDW AI algorithms have identified several promising drug candidates. CBDW has identified a target in the mitochondrial metabolism that has a role in oncology. CBDW then adds them to an ever-growing IP portfolio, including patents, trademarks, and trade secrets, enhancing its competitive advantage and potential for future revenue. The success and validation of the CBDW Sutra™ AI platform for AI-discovered drugs are testaments to its capabilities and the future it promises.
CBDW is dedicated to pushing the boundaries of drug discovery with its AI Drug Discovery (AIDD) player, Sutra™. With the CBDW AI-powered structure prediction algorithms, this platform has the potential to revolutionize drug discovery. It can design small molecules, optimize the design of antibodies and other proteins, and even repurpose drug molecules.
With a database of 19 viruses, the CBDW Sutra™ AI platform can predict and help prevent future pandemics. With access to a curated library of 8 million molecules, the CBDW platform makes possible the discovery of new drugs that precisely target neutralizable epitopes on viruses to enhance the potency and efficacy of existing therapies. The CBDW Sutra™ team's unwavering dedication to leveraging microbiome samples to identify new biomarkers for neurodegenerative diseases instills hope for future medical breakthroughs.
CBDW harnesses the power of AI to revolutionize drug repurposing, offering a cost-effective alternative to developing new drugs from the ground up. Drug repurposing involves identifying potential new applications for existing compounds, which can be time-consuming and labor-intensive. However, AI algorithms can analyze existing drug databases and identify potential new applications for these compounds in a fraction of the time, making it a game-changer in the pharmaceutical industry. CBDW is exploring synergizing AI with suitable linkers between antibodies and drugs to promote multi-drug combinations. This approach will bring new therapeutics to market with more substantial impacts than combination therapies and address unmet medical needs, expediting drug discovery and regulatory approvals.
Strategic Investment to Revolutionize AI-Driven Drug Discovery
On September 17th CBDW announced it had signed a Letter of Intent to acquire a strategic stake in Adnexus Biotechnologies Inc.
This strategic investment exemplifies the CBDW commitment to advancing its technological capabilities and expanding its reach in the AI sector. Integrating cutting-edge AI research and development into its portfolio underscores the CBDW aim to impact the AI sector, healthcare, and biotechnology significantly. This collaboration has the potential to push the boundaries of what is achievable in these fields.
For more information on $CBDW visit https://www.adnexusbiotech.com
and https://cbdw.ai/
Media Contact
Company Name: 1606 Corp.
Contact Person: Gaurav Chandra, CEO
Email: Send Email
Phone: (602) 481-1544
Address:2425 East Camelback Road Suite 150
City: Phoenix
State: AZ 8501
Country: United States
Website: https://www.adnexusbiotech.com
